CD4 and neoplasm: Similarly, systemic treatment of tumor-free mice with (R)-crizotinib, alone or in combination with CDDP (Supplementary Fig. 13j), failed to affect the expression of these factors by splenic CD4+ and CD8+ T lymphocytes (Supplementary Fig. 13k–p), neither affected those factors by lymph nodes’ CD4+ and CD8+ T lymphocytes (data not shown).